Results 11 to 20 of about 32,832 (202)

Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling

Cells, 2021
FGFR (fibroblast growth factor receptor) signaling controls fundamental processes in embryonic, fetal and adult human life. The magnitude, duration, and location of FGFR signaling must be strictly controlled in order to induce the correct biological ...
Jørgen Wesche, Ellen Margrethe Haugsten, Antoni Wiedlocha   +2 more
exaly   +4 more sources

Targeting FGFR inhibition in cholangiocarcinoma [PDF]

Cancer Treatment Reviews, 2021
Los colangiocarcinomas (CCA) son tumores raros pero agresivos de los conductos biliares, que a menudo se diagnostican en una etapa avanzada y tienen malos resultados en la terapia sistémica. Se han identificado alteraciones somáticas con implicaciones terapéuticas en casi la mitad de las CCA, en particular en la CCA intrahepática (iCCA), el subtipo que
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, John Bridgewater   +3 more
openaire   +5 more sources

FGFR Fusions in the Driver's Seat [PDF]

Cancer Discovery, 2013
Abstract Summary: Through a clinical deep sequencing protocol, Wu and colleagues have identified multiple FGFR fusion proteins in diverse cancers. Pharmacologic inhibition of FGFR suppressed the growth of FGFR fusion–positive tumor models, suggesting that these FGFR fusions are oncogenic drivers and highlighting the use of streamlined ...
Sabnis, Amit J, Bivona, Trever G
openaire   +6 more sources

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer [PDF]

Nature Communications
Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity.
David C. Müller, Andrew J. Murtha, Jack V. W. Bacon, Maria Stephenson, Connor Wells, Carlos Vasquez-Rios, Kimia Rostin, Lisa Rebane, Elena Schönlau, Jussi Nikkola, Nimira Alimohamed, Naveen S. Basappa, Daygen Finch, Jenny J. Ko, Jean-Michel Lavoie, Lucia Nappi, Krista Noonan, Michael Ong, Guliz Ozgun, Sunil Parimi, Maryam Soleimani, Srikala S. Sridhar, Paul Toren, Eric Winquist, Cecily Q. Bernales, Melissa Koudjanian, Jaskirat Atwal, Emily Fung, Laiba Khan, Bryndan Eigl, Dalia Othman, Tarek A. Bismar, Gang Wang, Reem Merza, Andreas I. Papadakis, Alan Spatz, Christian Kollmannsberger, Corinne Maurice-Dror, Matti Annala, Kim N. Chi, Gillian Vandekerkhove, Alexander W. Wyatt, Bernhard J. Eigl   +42 more
doaj   +2 more sources

Lighting up FGFR Signaling

Chemistry & Biology, 2014
In this issue of Chemistry & Biology, Kim and colleagues describe their work on optogenetic control of fibroblast growth factor receptor (FGFR) signaling. By engineering a chimeric receptor, the authors demonstrate that FGFR intracellular signaling can be controlled in space and time by blue light.
Zhang, Kai, Cui, Bianxiao
openaire   +3 more sources

Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma

Pharmacological Research
Immune checkpoint inhibitors (ICIs) are essential for urothelial carcinoma (UC) treatment. Fibroblast growth factor receptor (FGFR) alterations, as common oncogenic drivers in UC, have been reported to drive T cell depletion of UC immune microenvironment
Yuxuan Song, Shan Jiang, Yun Peng, Caipeng Qin, Yiqing Du, Tao Xu   +5 more
doaj   +2 more sources

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer

Cells, 2021
Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in non-small cell lung cancer (NSCLC)
Laura Pacini, Paul H Huang, Laura Pacini   +2 more
exaly   +3 more sources

377 FGFR protein phosphorylation as a biomarker for FGFR-targeted therapy in cholangiocarcinoma [PDF]

Journal of Clinical and Translational Science
Objectives/Goals: Cholangiocarcinoma is an aggressive cancer with a poor prognosis. Fibroblast Growth Factor Receptor 2 fusions are therapeutic targets in ~20% of cholangiocarcinoma, which restricts their benefit to only a subset of patients.
Zachary Risch, Julie Reeser, Michele Wing, Amy Smith, Thuy Dao, Eric Samorodnitsky, Emanuel Petricoin, Sameek Roychowdhury   +7 more
doaj   +2 more sources

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial [PDF]

Cancer Discovery, 2016
Abstract FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level clonal FGFR2 amplification have a high response rate to the selective FGFR inhibitor AZD4547, whereas cancers with ...
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., Cutts, R., Campbell, J., Ning, J., Fenwick, K., Swain, A., Brown, G., Chua, S., Thomas, Anne, Johnston, S. R., Ajaz, M., Sumpter, K., Gillbanks, A., Watkins, D., Chau, I., Popat, S., Cunningham, D., Turner, N. C.   +26 more
openaire   +6 more sources

Unraveling the FGFR–RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose [PDF]

Acta Pharmaceutica Sinica B
Fibroblast growth factor receptor (FGFR) signaling is a pivotal regulator of tumor progression, driving cell proliferation, survival, metastasis, and therapeutic resistance across diverse cancer types.
Xuquan Xian, Ruyi Gong, Shunzi Rong, Zhihao Zhang, Fengtong Jia, Lin Li, Zhengguo Chen, Beatrice Eymin, Tao Jia   +8 more
doaj   +2 more sources